Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response.
Journal: Journal for immunotherapy of cancer
Published: October 11, 2024
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
Journal: Gynecologic oncology
Published: August 09, 2024
A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 22, 2022
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial.
Journal: JAMA oncology
Published: November 03, 2022
Renal toxicity with liposomal doxorubicin in metastatic breast cancer.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: September 02, 2018
Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo.
Journal: Journal for immunotherapy of cancer
Published: February 11, 2016
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers.
Journal: Cancer immunology, immunotherapy : CII
Published: May 07, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026